Multi-peptide blend reconstituted with bacteriostatic water 4-in-1 anti-aging peptide blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg
This is the first controlled study to evaluate the combined use of an incretin therapy (GLP-1 agonist) used with a PsA biologic, and show benefit
Gastrointestinal events were the most common side effects, and discontinuation due to adverse events occurred more often in retatrutide groups than in placebo
Henseler for his pivotal early genetic and epidemiological research and his contribution to the psoriasis field
The current results show that number needed to benefit (NNTB) was 207 (95%CI: NNTB 129 to NNTB 620, Follow-up time: 3.48 1.51 years) for total MI, NNTB 67 (95%CI: NNTB 46 to NNTB 135, Follow-up time: 3.48 1.51 years) for MACE, NNTB 170 (95%CI: NNTB 120 to NNTB 306, Follow-up time: 3.48 1.51 years) for cardiovascular mortality, and NNTB 93 (95%CI: NNTB 52 to NNTB 1717, Follow-up time: 3.45 1.21 years) for coronary revascularization